Terrance P. Coyne is CFO & VP at Royalty Pharma plc (RPRX). They have made 9 open-market trades across 1 company since 2020, most recently 2026-08-13.
CIK 0001814876
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $83K since 2020, against 8 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| RPRX | 1,772 | $108K |
Shares reported on the most recent Form 4, priced at the 2026-08-17 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| RPRX | SELL · 10b5-1 | 2026-08-13 | 2026-08-17 | $58.68 | $646K | +3.5% | -2.2% | — |
| RPRX | SELL · 10b5-1 | 2026-05-26 | 2026-05-28 | $53.98 | $3.5M | +2.2% | +5.0% | +13.6% |
| RPRX | SELL · 10b5-1 | 2026-04-28 | 2026-04-30 | $49.78 | $1.7M | +3.5% | +10.4% | +18.4% |
| RPRX | SELL · 10b5-1 | 2026-04-01 | 2026-04-02 | $48.33 | $1.7M | +1.5% | +4.6% | +16.2% |
| RPRX | SELL · 10b5-1 | 2026-03-23 | 2026-03-25 | $45.53 | $3.2M | -0.2% | +5.2% | +17.9% |
| RPRX | SELL | 2026-03-02 | 2026-03-04 | $46.78 | $1.6M | -2.0% | +0.6% | +14.8% |
| RPRX | SELL · 10b5-1 | 2026-02-23 | 2026-02-25 | $45.32 | $1.6M | +1.4% | +2.5% | +19.1% |
| RPRX | SELL | 2026-02-02 | 2026-02-04 | $42.54 | $10.4M | +4.2% | +4.2% | +15.8% |
| RPRX | SELL · 10b5-1 | 2026-01-20 | 2026-01-23 | $39.35 | $2.7M | +8.1% | +12.5% | +22.8% |
| RPRX | SELL | 2026-01-02 | 2026-01-06 | $38.42 | $2.7M | -2.7% | +8.5% | +16.4% |
| RPRX | SELL · 10b5-1 | 2025-12-15 | 2025-12-17 | $38.36 | $5.2M | +1.8% | +3.2% | +20.4% |
| RPRX | SELL · 10b5-1 | 2025-12-01 | 2025-12-03 | $39.87 | $5.5M | -2.5% | -1.6% | +20.2% |
| RPRX | SELL · 10b5-1 | 2025-11-24 | 2025-11-26 | $38.56 | $5.3M | -4.8% | -1.9% | +13.5% |
| RPRX | SELL · 10b5-1 | 2025-11-17 | 2025-11-19 | $39.30 | $5.3M | +2.1% | -0.3% | +17.3% |
| RPRX | SELL · 10b5-1 | 2023-08-09 | 2023-08-11 | $30.74 | $2.3M | -2.1% | -4.3% | -9.6% |
| RPRX | SELL · 10b5-1 | 2023-07-12 | 2023-07-14 | $31.00 | $2.3M | +2.4% | -1.2% | -11.1% |
| RPRX | SELL | 2022-11-08 | 2022-11-10 | $43.47 | $1.1M | -1.0% | -3.7% | -13.2% |
| RPRX | SELL | 2022-11-02 | 2022-11-04 | $43.06 | $237K | +1.6% | +2.7% | -7.1% |
| RPRX | SELL | 2022-08-01 | 2022-08-03 | $43.19 | $1.3M | +3.3% | -1.1% | -0.7% |
| RPRX | SELL | 2021-03-03 | 2021-03-05 | $44.79 | $9.0M | +11.0% | -2.5% | -0.3% |
| RPRX | SELL | 2021-03-02 | 2021-03-04 | $46.94 | $9.4M | +9.3% | -0.5% | +0.1% |
| RPRX | BUY | 2020-06-18 | 2020-06-23 | $28.00 | $83K | -10.2% | -16.5% | -21.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.